| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -19,128 | -11,666 |
| Cost of share-based payments | 4,556 | 3,099 |
| Increase in other current assets | 71 | 140 |
| Increase/(decrease) in accounts payable | 3,941 | 2,479 |
| Decrease in accrued liabilities | -775 | -838 |
| Decrease in employee compensation and benefits | -558 | -475 |
| Net cash used in operating activities | -12,035 | -7,541 |
| Proceeds from issuance of common shares-At Market Offering | 15,437 | 1,887 |
| Issuance costs-At Market Offering | 466 | 59 |
| Proceeds from issuance of common shares-Public Offering | 15,525 | 15,525 |
| Issuance costs-Public Offering | 1,552 | 1,552 |
| Net cash provided by financing activities | 28,944 | 15,801 |
| Net cash provided by (used in) investing activities | - | 0 |
| Increase/(decrease) in cash and cash equivalents | 16,909 | 8,260 |
| Cash and cash equivalents at beginning of period | 18,533 | - |
| Cash and cash equivalents at end of period | 35,442 | - |
Nuvectis Pharma, Inc. (NVCT)
Nuvectis Pharma, Inc. (NVCT)